Using Novilase Laser Therapy to Treat Small Breast Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical evaluation focuses on the effectiveness of Novilase laser therapy for the focal destruction of malignant breast tumors measuring 15 mm or less. Participants will undergo a screening MRI, followed by a laser ablation procedure, and will be monitored with an MRI and excision at 4-6 weeks post-treatment. The study aims to demonstrate that Novilase can achieve a complete tumor ablation rate exceeding 87.85%, compared to the standard lumpectomy procedure. This pivotal study builds on previous findings where 98% of similar tumors were successfully ablated in one session.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Females, aged 18 years and older
* Able to give written informed consent herself
* Definitive pathologic diagnosis by needle core biopsy
* Unifocal malignant tumor (T1a-c, N0-1, M0) that does not exceed 15 mm in longest dimension and measures at least 5 mm away from the skin and chest wall, or can be moved at least 5 mm away from the skin and chest wall by injection of saline or local anesthetic
* No more than 10 mm of calcifications confined to the tumor on imaging
* Tumor is well visualized through ultrasound or x-ray mammography imaging and amenable to image-guidance therapy (i.e., a tumor which is well visualized through imaging can be identified from surrounding breast tissue and does not have margins obscured by other structures or artifacts on the images)
* Tumor is well visualized on MRI
* Subject with mammographic appearance of overall dense parenchymal tissue may be included, as long as a clearly evident marker is present at tumor site
* Tumor with less than 25% intraductal component, as determined by core biopsy
* No clinically significant co-morbidities (e.g., chronic illnesses existing simultaneously with and usually independent of breast cancer) that affect life expectancy
* Subject weight limited to ≤300 lbs. or ≤136 kg
* Subject agrees to comply with standard of care radiation or adjuvant therapy as prescribed by physician

Exclusion Criteria:

* Subject younger than 18 years of age
* Pregnant or breast-feeding
* Tumor poorly visualized by ultrasound or x-ray mammography imaging
* Contraindications to administration of gadolinium-based contrast agent, including: prior allergic reaction to a gadolinium-based contrast agent, moderate to end-stage kidney disease, and/or acute or chronic severe renal insufficiency (Glomerular filtration rate (GFR) \<30ml/min/1.73 sq. meters)
* Contraindications to MRI according to site guidelines (e.g., cardiac pacemaker, metallic implants)
* History of severe asthma
* Tumor measuring greater than 15 mm in longest dimension
* Microcalcifications that extend beyond target tumor such that overall longest dimension of target tumor and calcifications is longer than 15 mm.
* Advanced stage breast cancer
* Tumors that are lobular neoplasm, metastatic carcinoma to breast, sarcoma, Phyllodes tumor, or Paget's disease
* Tumor with only DCIS with microinvasion
* Extensive intraductal component in lesion (i.e., \>25%) as determined by core biopsy
* Subject who is known to be BRCA positive
* Tumor that is ER/PR/HER2 negative (TNBC)
* Inability to lie in prone or supine position for one hour
* Subject who is currently participating in another investigational treatment, device or drug study through follow up that would interfere with this trial
* Subject without a definitive HER2 test according to ASCO/CAP guidelines

Where it's running

• UC San Diego Health
  La Jolla, California, United States Recruiting
• Eisenhower Health
  Rancho Mirage, California, United States Recruiting
• Yale University
  New Haven, Connecticut, United States Recruiting
• Buffalo General Medical Center
  Buffalo, New York, United States Recruiting
• St. Elisabeth-Krankenhaus Köln-Hohenlind
  Cologne, Germany Recruiting
• Ichilov | Tel Aviv Sourasky Medical Center
  Tel Aviv, Israel Recruiting

Study contacts

• Principal investigator: John Lewin, MD — Yale University
• Study coordinator: Eugene Bajorinas
• Email: ebajorinas@novianhealth.com
• Phone: 3122667200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CSF sample collection from people with metastatic breast cancer to see brain metastasis risk

  This study tests whether spinal fluid and other samples can help predict brain metastases in adults with metastatic HER2-positive or triple-negative breast cancer who have not yet shown brain involvement.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619534

• ENLIGHT algorithm to find treatment options for advanced metastatic breast cancer

  This test uses the ENLIGHT algorithm to try to find approved drugs that might work better for adults with triple-negative or endocrine therapy–resistant metastatic breast cancer.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07067138

• HTR2 CAR T Cells Targeting HER2 in Metastatic Breast Cancer

  A one-time treatment with specially modified T cells that target HER2-positive metastatic breast cancer is tested to see if it’s safe and how long the cells last, with a plan for possible dose increases.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas · NCT06251544

• Comparing different radiotherapy methods for early breast cancer after surgery

  This study is testing different types of radiation therapy for women with early breast cancer after surgery to see which method works best to lower the chance of cancer coming back.

  Recruiting Instituto Brasileiro de Controle do Cancer · São Paulo, São Paulo · NCT04669873

• Revaree Plus for vaginal dryness in people with breast cancer

  This trial will test whether Revaree Plus can improve vaginal dryness and related discomfort in adults with hormone-receptor–positive stage 0–III breast cancer who are on tamoxifen, aromatase inhibitors, or SERMs.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07042581

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.